Cat. No. 3810
Chemical Name: N,N'-Dihydroxyoctanediamide
Biological ActivityHistone deacetylase (HDAC) inhibitor (ID50 values are 0.25 and 0.3 μM for HDAC1 and HDAC3 respectively). Potentiates the cytostatic effects of 5-Fluorouracil (Cat. No. 3257) in colorectal cancer cells.
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Richon et al (1998) A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc.Natl.Acad.Sci.U.S.A 95 3003. PMID: 9501205.
Brinkmann et al (2001) Histone hyperacetylation induced by histone deacetylase inhibitors is not sufficient to cause growth inhibition in human dermal fibroblasts. J.Biol.Chem. 276 22491. PMID: 11304533.
Zhang et al (2004) The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells. Mol.Cancer.Ther. 3 425. PMID: 15078986.
If you know of a relevant citation for this product please let us know.
Keywords: SBHA, supplier, HDAC, inhibits, inhibitors, histone, deacetylases, induces, inducers, of, apoptosis, epigenetics
Find multiple products by catalog number
New Products in this Area
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.